Authorities in India have
revoked a GlaxoSmithKline patent
on the salt form of lapatinib, which
is the active ingredient in GSK’s
breast cancer treatment Tykerb.
However the patent on the
original compound, which remains
valid until 2019, was upheld, with
the move following a challenge by
Fresenius Kabi Oncology.
Fresenius Kabi had challenged
both patents on the basis that they
lacked innovation.
The patent on the lapatinib
salt would have extended GSK’s
exclusivity on the product to 2021.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Aug 13
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FROM 01 May, pharmacists will be able to dispense Verzenio (abemaciclib) through the PBS to treat Australian patients with an invasive form of early breast cancer that is at high risk of recurring after initial treatment.
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.